These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 18855533)

  • 21. Implications of Polymorphisms in the BCKDK and GATA-4 Gene Regions on Stable Warfarin Dose in African Americans.
    Bargal SA; Kight JN; Augusto de Oliveira F; Shahin MH; Langaee T; Gong Y; Hamadeh IS; Cooper-DeHoff RM; Cavallari LH
    Clin Transl Sci; 2021 Mar; 14(2):492-496. PubMed ID: 33278335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.
    Li T; Lange LA; Li X; Susswein L; Bryant B; Malone R; Lange EM; Huang TY; Stafford DW; Evans JP
    J Med Genet; 2006 Sep; 43(9):740-4. PubMed ID: 16611750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CYP2C9 and VKORC1 polymorphisms influence warfarin dose variability in patients on long-term anticoagulation.
    Santos PC; Dinardo CL; Schettert IT; Soares RA; Kawabata-Yoshihara L; Bensenor IM; Krieger JE; Lotufo PA; Pereira AC
    Eur J Clin Pharmacol; 2013 Apr; 69(4):789-97. PubMed ID: 22990331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic determinants of variability in warfarin response after the dose-titration phase.
    Iwuchukwu OF; Ramirez AH; Shi Y; Bowton EA; Kawai VK; Schildcrout JS; Roden DM; Denny JC; Stein CM
    Pharmacogenet Genomics; 2016 Nov; 26(11):510-516. PubMed ID: 27632229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
    Perera MA; Cavallari LH; Limdi NA; Gamazon ER; Konkashbaev A; Daneshjou R; Pluzhnikov A; Crawford DC; Wang J; Liu N; Tatonetti N; Bourgeois S; Takahashi H; Bradford Y; Burkley BM; Desnick RJ; Halperin JL; Khalifa SI; Langaee TY; Lubitz SA; Nutescu EA; Oetjens M; Shahin MH; Patel SR; Sagreiya H; Tector M; Weck KE; Rieder MJ; Scott SA; Wu AH; Burmester JK; Wadelius M; Deloukas P; Wagner MJ; Mushiroda T; Kubo M; Roden DM; Cox NJ; Altman RB; Klein TE; Nakamura Y; Johnson JA
    Lancet; 2013 Aug; 382(9894):790-6. PubMed ID: 23755828
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
    Miyagata Y; Nakai K; Sugiyama Y
    Int Heart J; 2011; 52(1):44-9. PubMed ID: 21321468
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin.
    Yuen E; Gueorguieva I; Wise S; Soon D; Aarons L
    J Pharmacokinet Pharmacodyn; 2010 Feb; 37(1):3-24. PubMed ID: 19941044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans.
    Voora D; Koboldt DC; King CR; Lenzini PA; Eby CS; Porche-Sorbet R; Deych E; Crankshaw M; Milligan PE; McLeod HL; Patel SR; Cavallari LH; Ridker PM; Grice GR; Miller RD; Gage BF
    Clin Pharmacol Ther; 2010 Apr; 87(4):445-51. PubMed ID: 20200517
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Haplogroup analysis of vitamin-K epoxide reductase (VKORC1) gene: novel element in the optimization of anticoagulant therapy].
    Sipeky C; Melegh B
    Orv Hetil; 2008 Sep; 149(39):1839-44. PubMed ID: 18805772
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of common and rare genetic variation on warfarin dose among African-Americans and European-Americans using the exome array.
    Liu N; Irvin MR; Zhi D; Patki A; Beasley TM; Nickerson DA; Hill CE; Chen J; Kimmel SE; Limdi NA
    Pharmacogenomics; 2017 Jul; 18(11):1059-1073. PubMed ID: 28686080
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.
    Hernandez W; Gamazon ER; Aquino-Michaels K; Smithberger E; O'Brien TJ; Harralson AF; Tuck M; Barbour A; Cavallari LH; Perera MA
    J Thromb Haemost; 2017 Apr; 15(4):735-743. PubMed ID: 28135054
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population.
    Mitchell C; Gregersen N; Krause A
    Pharmacogenomics; 2011 Jul; 12(7):953-63. PubMed ID: 21635147
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interethnic variability of warfarin maintenance requirement is explained by VKORC1 genotype in an Asian population.
    Lee SC; Ng SS; Oldenburg J; Chong PY; Rost S; Guo JY; Yap HL; Rankin SC; Khor HB; Yeo TC; Ng KS; Soong R; Goh BC
    Clin Pharmacol Ther; 2006 Mar; 79(3):197-205. PubMed ID: 16513444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. VKORC1 -1639G>A and CYP2C9*3 are the major genetic predictors of phenprocoumon dose requirement.
    Puehringer H; Loreth RM; Klose G; Schreyer B; Krugluger W; Schneider B; Oberkanins C
    Eur J Clin Pharmacol; 2010 Jun; 66(6):591-8. PubMed ID: 20376629
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.
    Valentin II; Vazquez J; Rivera-Miranda G; Seip RL; Velez M; Kocherla M; Bogaard K; Cruz-Gonzalez I; Cadilla CL; Renta JY; Feliu JF; Ramos AS; Alejandro-Cowan Y; Gorowski K; Ruaño G; Duconge J
    Ann Pharmacother; 2012 Feb; 46(2):208-18. PubMed ID: 22274142
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin.
    Limdi NA; McGwin G; Goldstein JA; Beasley TM; Arnett DK; Adler BK; Baird MF; Acton RT
    Clin Pharmacol Ther; 2008 Feb; 83(2):312-21. PubMed ID: 17653141
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
    Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
    Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
    Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
    Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.